Which malignancies have shown benefit from ivermectin, and what dosing protocol is recommended?

Ivermectin Has NOT Been Proven to Treat Any Cancer in Humans

Based on current medical evidence, ivermectin should NOT be used for cancer treatment outside of properly designed clinical trials. While preclinical laboratory studies show promising anticancer activity, there are no FDA-approved indications for ivermectin in cancer, and no large-scale randomized controlled trials have demonstrated clinical benefit in cancer patients 1.

FDA-Approved Uses Only

Ivermectin is FDA-approved exclusively for:

• Strongyloidiasis: 200 mcg/kg as a single oral dose on an empty stomach 1
• Onchocerciasis: 150 mcg/kg as a single oral dose, with retreatment intervals as short as 3 months 1

These are parasitic infections, not malignancies.

The Preclinical-Clinical Evidence Gap

What Laboratory Studies Show (NOT Clinical Evidence)

Preclinical research demonstrates ivermectin's anticancer mechanisms in test tubes and animal models:

• Osteosarcoma: Synergistic effects with doxorubicin through oxidative stress and mitochondrial dysfunction at clinically feasible doses 2
• Ovarian cancer: Enhanced cisplatin efficacy by suppressing Akt/mTOR signaling; complete tumor reversal in mouse models when combined with cisplatin 3
• Breast cancer: Cell cycle arrest, reduced viability in multiple cell lines (MDA-MB-231, MDA-MB-468, MCF-7); synergistic with docetaxel, cyclophosphamide, and tamoxifen 4; inhibition of EMT via Wnt signaling in endocrine-resistant cells 5
• T-cell lymphoma: Mitochondrial-dependent apoptosis with IC₅₀ of 10.55 µg/mL; tumor size reduction in mice 6

Critical Problem: No Human Clinical Trials

The most recent comprehensive review (2025) explicitly states there are NO large-scale randomized controlled trials confirming therapeutic benefits in human cancer patients 7. A 2026 observational study of 197 cancer patients using ivermectin/mebendazole reported self-reported outcomes (84.4% "clinical benefit ratio"), but this lacks the rigor of controlled trials and relies on subjective patient reporting rather than objective tumor measurements 8.

Real-World Risks

Documented Harms

• Treatment abandonment: Patients may delay or forgo proven cancer therapies (chemotherapy, radiation, surgery) in favor of unproven ivermectin 7
• Toxicity from self-medication: Social media misinformation drives inappropriate dosing, leading to adverse events in oncology patients 7
• False hope: Anecdotal reports from Ecuador show 19% of cancer patients using ivermectin as alternative therapy, but specialists confirm no scientific authorization for such use 9

Dose-Dependent Side Effects

When used off-label at higher doses, ivermectin causes primarily gastrointestinal symptoms (25.4% incidence), though most are mild and dose-dependent 8. Standard parasitic dosing shows minimal side effects 10.

Clinical Recommendation Algorithm

For any patient asking about ivermectin for cancer:

1. Acknowledge the preclinical data exists but emphasize it does NOT translate to proven human benefit
2. Strongly discourage use outside clinical trials—no established dosing protocol exists for cancer
3. Redirect to evidence-based oncology care: chemotherapy, targeted therapy, immunotherapy, radiation, surgery as appropriate
4. Screen for misinformation exposure: Ask about social media sources driving interest
5. Offer clinical trial enrollment if available, as this is the ONLY appropriate context for ivermectin cancer use

Common Pitfalls to Avoid

• Do not equate laboratory activity with clinical efficacy: The concentrations showing anticancer effects in vitro often exceed achievable human plasma levels 11
• Do not provide dosing guidance: There is no established cancer treatment protocol; parasitic dosing (150-200 mcg/kg) has no validated application in oncology
• Do not dismiss patient concerns: Acknowledge financial pressures and desperation that drive alternative therapy seeking, but firmly redirect to proven treatments

The Bottom Line

Ivermectin remains an antiparasitic drug with intriguing but unproven anticancer properties. The translational gap between promising laboratory results and absent clinical trial data means it cannot be recommended for cancer treatment 7. Healthcare providers must counter misinformation while supporting rigorous clinical trials to determine if ivermectin has any legitimate role in oncology.